Ovilla-Martínez R, Cota-Rangel X, Báez-Islas P

Idioma: Español
Referencias bibliográficas: 12
Paginas: 112-116
Archivo PDF: 271.27 Kb.

RESUMEN

La leucemia linfocítica crónica es una neoplasia linfoproliferativa de grado bajo caracterizada por ≥ 5 x 109/L linfocitos B clonales en sangre periférica que expresan CD5, CD19, dimCD20 y CD231. En este artículo se describen los enfoques más recientes para realizar el abordaje terapéutico de esta enfermedad. Es necesario individualizar el tratamiento de la leucemia linfocítica crónica con el uso de las herramientas de pronóstico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol [Internet]. 2017 Sep 1 [citado 2019 Mar 29];92(9):946–65. Disponible en: http://doi.wiley.com/10.1002/ajh.24826

2. Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2018. Parikh Blood Cancer J [Internet]. 2018 [citado 2019 Mar 29];8:93. Disponible en: https://www.nature. com/articles/s41408-018-0131-2.pdf

3. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Hillmen P, et al. Special Report iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL [Internet]. 2018 [citado 2018 Aug 22]. Disponible en: www. bloodjournal.org

4. Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-Then and now. Am J Hematol 2016; Mar;91(3):330-40. doi: 10.1002/ajh.24282.

5. International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 2016; Jun;17(6):779-790. doi: 10.1016/S1470-2045(16)30029-8. Epub 2016 May 13.

6. Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, et al. NCCN Guidelines Panel Disclosures Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Internet] 2018 [citado 2018 Aug 23]. Disponible en: https:// www.nccn.org/professionals/physician_gls/pdf/cll.pdf

7. Burke JM, Sharman JP. Hematology 2018: Lymphomas/ CLL - Lymphomas/CLL - 2018 ASH Annual Meeting - Oncology - Clinical Care Options [Internet]. 2019 [citado 2019 Mar 29]. Disponible en: https://www.clinicaloptions. com/oncology/conference-coverage/hematology-2018/ lymphomas-cll/ea

8. Barr P, Robak T, Owen CJ, Tedeschi A, Bairey O, Bartlett NL, et al. Updated Efficacy and Safety from the Phase 3 Resonate- 2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood [Internet] 2016 [citado 2018 Aug 23];128(22). Disponible en: http:// www.bloodjournal.org/content/128/22/234

9. O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE- 17): a phase 2, open-label, multicentre study. Lancet Oncol [Internet] 2016 Oct 1 [citado 2018 Aug 23];17(10):1409–18. Disponible en: http://www.ncbi. nlm.nih.gov/pubmed/27637985

10. Sharma S, Rai KR. Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options. Cancer [Internet] 2019 Feb 26 [citado 2019 Mar 29]; Disponible en: http://doi.wiley.com/10.1002/cncr.31931

11. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2016; Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.

12. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018; Mar 22;378(12):1107-1120. doi: 10.1056/ NEJMoa1713976.